London: Alnylam Pharmaceuticals said on Monday that its drug vutrisiran met the main goal in a late-stage study testing it as a treatment for patients with a rare heart disease, sending the drugmaker’s shares up 37% in premarket trading.

Data from a keenly-awaited trial shows that the drug helped reduce deaths and heart-related events by 28% across all trial patients and by 33 per cent in patients who only received vutrisiran.

The study tested adults with transthyretin amyloid cardiomyopathy (ATTR-CM), where the heart muscles are restricted due to the accumulation of irregular proteins.

The study enrolled 655 patients who were randomized to receive Alnylam’s drug or placebo during the trial.

Treatment with the drug also resulted in statistically significant improvements across all secondary goals, including measures such as the distance patients could walk in six minutes.

Vutrisiran is also approved in the U.S. under the brand name Amvuttra to treat nerve damage in adult patients for another condition known as hereditary ATTR amyloidosis.

Alnylam said it will proceed with global regulatory submissions starting later this year, including to the U.S. Food and Drug Administration.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Sonia Cheema)

  • Published On Jun 24, 2024 at 05:52 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App